Recenzija, prikaz
https://doi.org/10.3325/cmj.2021.62.95
Could fluvoxamine keep COVID19 patients out of hospitals and intensive care units?
Robert Marčec
; University of Zagreb School of Medicine, Zagreb, Croatia
Robert Likić
; Unit for Clinical Pharmacology, Department of Internal Medicine, Clinical Hospital Center Zagreb, Zagreb, Croatia
Sažetak
Since December 2019, when the first cases of coronavirus
disease 2019 (COVID-19) were reported in Wuhan, China,
SARS-CoV-2 has caused a global pandemic, with more than
75 million cases and over 1.6 million deaths worldwide (1).
The international community has invested enormous resources in the development of safe and effective vaccines,
which were registered and approved for widespread use
in record time. Nevertheless, limited production capacities
and vaccine hesitancy could impede a global post-COVID19 recovery, particularly in developing countries.
Ključne riječi
Hrčak ID:
278049
URI
Datum izdavanja:
25.2.2021.
Posjeta: 474 *